Evolus Inc. (NASDAQ: EOLS) watched its shares come crashing down on Wednesday after the company announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for one of its drugs. Specifically, the agency singled out DWP-450 for the treatment of glabellar lines, also known as frown lines, in adult patients.
In the CRL, deficiencies cited by the FDA were isolated to items related to Chemistry, Manufacturing, and Controls (CMC) processes. No deficiencies were related to clinical or nonclinical matters. Evolus expects to respond with a complete submission to FDA within 90 days.
At the same time, the FDA issued an Establishment Inspection Report (EIR) to Daewoong Pharmaceutical confirming the favorable completion of its preapproval inspection of Daewoong’s manufacturing facility in South Korea, which was purpose-built for production of DWP-450.
The DWP-450 manufacturing facility is fully validated by Daewoong under current good manufacturing practice requirements and has capacity expected to meet anticipated product demand. Evolus plans to utilize the Daewoong facility to support commercial production following the anticipated approval of DWP-450.
David Moatazedi, president and CEO of Evolus, commented:
The successful completion of the FDA inspection of the manufacturing facility and issuance of the EIR represents a key operational milestone and entirely concludes the pre-approval inspection process by the FDA.
He added:
We are pleased with the progress we continue to make with the FDA, and this CRL confirms our confidence in our clinical submission. Deficiencies cited within the CRL are isolated to CMC matters and we expect to respond comprehensively within 90 days. Overall, we view these updates as positive, which together give us the line of sight necessary to build our commercial infrastructure. We look forward to working closely with the FDA and remain committed to bringing DWP-450 to market by spring 2019.
Shares of Evolus were last seen down about 18% at $11.93, with a consensus analyst price target of $22.50 and a 52-week range of $6.75 to $17.50.
24/7 Wall St.In 20 Years, I Haven’t Seen A Cash Back Card This Good
After two decades of reviewing financial products I haven’t seen anything like this. Credit card companies are at war, handing out free rewards and benefits to win the best customers.
A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges.
Our top pick today pays up to 5% cash back, a $200 bonus on top, and $0 annual fee. Click here to apply before they stop offering rewards this generous.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.